Starting with comprehensive pre-formulation services to commercial manufacturing, we provide a full suite of services for formulations of oral, parenteral and topical dosage forms. We offer “Fit-for-purpose” formulation development for pre-clinical and First in Human (FIH) studies based on molecule’s physico-chemical behavior, excipient compatibility studies, and quick screening of excipients.
Our state- of-the-art formulation manufacturing facilities are in Hyderabad and Visakhapatnam and are audited by all major regulatory agencies.
Cross-functional teams such as DMPK, API synthesis, salt screening, toxicology, process engineering, analytical development and regulatory teams are located in the same campus and work in an integrated manner at each stage of the life cycle of the molecule for efficient and on-time delivery.
Service Offerings:
Oral Dosage Forms
We offer integrated oral dosage form services right from pre-formulation services to commercial manufacturing. We provide recommendations for best dosage form to clinic, based on the preformulation study results and help customer to choose the phase appropriate dosage form that suites the therapeutic objective.
Pre-formulation services:
Our pre-formulation services include:- API physiochemical characterization
- Molecule stability behavior
- Solubility enhancement by various techniques
Based on API characteristics we provide recommendations for maximizing the bioavailability of the molecule through solubility and permeability enhancement, gastro retentive formulation and targeted drug delivery systems.
We offer pre-clinical supplies of formulations for animal studies from R&D. Our state of art lab facilities are equipped with miniature lab equipment that enables fit for purpose formulation development using minimum batch size as low as 50 g blend using minimal drug substance quantities.
We also offer support to veterinary formulations for development of customized formulation.
“Phase appropriate” dosage form development services for early phase clinical trials (Phase 1&2):
Insights from the pre-formulation and preclinical studies would be taken into consideration while designing dosage forms like tablets, capsules, oral liquids.
In addition to conventional approaches, we have expertise in
- Masking the taste of the bitter tasting drugs, support to select the type and level of sweetener, flavours, complexation agents using ‘e-tongue technology’.
- Xcelodose technology to directly fill the API in capsule with an accuracy of about 100 microgram to bring your NCE molecule right from preclinical stage to clinical stage in a cost effective manner.
- Multi unit particulate systems (MUPS) to achieve tailored drug release of actives in fixed dose combination to enable immediate and modified release of multiple active ingredients.
Late phase formulation development for Phase 3/Commercial supply:
We offer wide variety of dosage forms for late phase development up to commercial manufacturing. Our state of art laboratory equipment help to develop robust formulation using QbD approach and evaluate impact of formulation variables and critical material/process variables on drug product quality attributes during the lab scale development and provide recommendations for successful scale up and registration batches.
In addition to traditional dosage forms, we have the capability to develop and manufacture highly complex formulations involving bi-layer tablets, multi-particulate systems (Pellets or Mini-tablets in capsules), fixed dose combinations, very low and high-dose products, modified release formulations, oral solutions and suspensions. We provide patient centric solutions for the dosage form design.
We have access to state of art manufacturing facilities that are approved by US FDA, MHRA and WHO to enable seamless cGMP manufacturing of clinical/registration and commercial batches. Most of the manufacturing facilities follow paperless electronic BMR systems and comply to stringent regulatory requirements.
Parenteral Dosage Forms
Our depth and breadth of experience and specialization in parenteral dosage form development is remarkable which can provide insight and innovation. We offer the expertise in overcoming the challenges associated with parenteral drug product development such as but not limited to.
- Solubility enhancement studies
- Achieving a good compatibility of the drug substances with the excipients
- Establishing the compatibility of the preparations with the container closure system
- Stability challenges
A constant focus on key control measures from pre-formulation development through drug product development to GMP manufacturing is provided to meet time-to-market schedules within the prescribed budget. With a portfolio of options to choose from, we partner with customers to find the approach that best achieves their technical goals.
Fig: Flow diagram for services offered in Parenteral dosage forms
Parenteral formulation development includes following activities but not limited to identification, selection and optimization of:
- Formulation composition (solubility enhancers, isotonicity agents, chelating agents, bulking agents, anti-oxidants, preservatives etc)
- Process and process parameters (mixing speed and mixing time, process temperature, order of addition of excipients etc)
- Product Container closure system
- Other supporting studies such as in-use stability studies, preservative effectiveness testing, compatibility and hold time studies and stability studies, reconstitution studies and dilution studies
Our parenteral formulation development lab includes all the required equipments and also critical equipment such as
- Martin Christ 2-10D LSC plus pilot scale lyophilizer
- Bead Mill
- High pressure homogenizer
- Fedegari counter pressure autoclave
Our State of art manufacturing facilities for parenteral dosage forms are located at vishakapatnam and are approved by major regulatory agencies (MFDS/USFDA/MHRA)
Parenteral Dosage Forms
We offer formulation development through a skilled scientific team with expertise in Topical dosage forms both in conventional and microspheres based formulations
- Ointments
- Creams
- Gels
We provide tailor made solutions to address the challenges of topical dosage forms and help to optimize the development time and costs
Why Aurigene Pharmaceutical Services?
Fit-for-purpose development strategy
Integrated cross-functional teams such as PK-PD, API synthesis, salt screening, toxicology, process engineering, and analytical development teams
Services across the product lifecycle
USFDA inspected GMP facilities
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market